Delic Corp

Delic Corp is a psychedelic wellness company based in Vancouver, Canada. It was founded in 2020 by Jackee Stang and her husband (Delic’s CEO) Matt Stang. Delic is among the first publicly traded psychedelic companies. Good News Network reporter Andy Corbley wrote about Matt Stang’s and his wife Jackee’s intentions for the company to become a “distributive and educational entity that will immediately give thousands of people a place to safely purchase quality products, and get the best information about where psychedelic wellness centers are located.”

Delic pursues its goal of expanding patient access to psychedelic medicine through clinic operations, media outreach, and scientific research. 

Clinics

Delic owns “a self-sustaining ecosystem” of businesses that operate clinics across the United States. The company established what it describes on its website as “the largest chain of psychedelic wellness clinics to bring treatment to the mainstream” upon its November 2021 merger with Ketamine Wellness Centers (KWC). The acquisition expanded Delic’s network of ketamine therapy clinics to nine states. A newly launched program offers support to families of ketamine patients. 

Media

Delic’s media branch features an email newsletter, the news outlet Reality Sandwich (which it purchased, amid some controversy, in 2019), and a podcast called Delic Radio. The company also runs Meet Delic, an annual two-day conference connecting psychedelic researchers, entrepreneurs, psychonauts, and other “leading industry voices.”

Research

Delic Labs is “a licensed cannabis and psilocybin research laboratory with a focus on extraction optimization, analytical testing, and chemical process development.” Delic Labs materialized through Delic Corp’s acquisition and rebranding of Complex Biotech Discovery Ventures (CBDV) Ltd. Through this venture, Delic Corp is pursuing an IP portfolio of novel psychedelic compounds. The laboratory possesses a Health Canada Section 56 exemption for psilocybin and applied in October 2021 for exemptions to study other psychedelic compounds including MDMA and LSD.